logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11352440 B1

PDFFull Text
Date of Patent:
Jun. 07, 2022

Filed:

Aug. 30, 2018

Antibodies against cd73 and uses thereof

Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Nils Lonberg, Woodside, CA (US);

Alan J. Korman, Piedmont, CA (US);

Bryan C. Barnhart, San Francisco, CA (US);

Aaron P. Yamniuk, Lawrenceville, NJ (US);

Mohan Srinivasan, Cupertino, CA (US);

Karla A. Henning, Milpitas, CA (US);

Ming Lei, Princeton, NJ (US);

Emanuela Sega, Cupertino, CA (US);

Angela Goodenough, Morrisville, PA (US);

Maria N. Jure-Kunkel, Plainsboro, NJ (US);

Guodong Chen, East Brunswick, NJ (US);

John S. Sack, Lawrenceville, NJ (US);

Richard Y. Huang, Bridgewater, NJ (US);

Martin J. Corbett, Mount Holly, NJ (US);

Joseph E. Myers, Jr., Flemington, NJ (US);

Liang Schweizer, Cambridge, MA (US);

Sandra V. Hatcher, Hillsborough, NJ (US);

Haichun Huang, Fremont, CA (US);

Pingping Zhang, Cupertino, CA (US);

Assignee:

BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US);

Attorneys:

Nelson Mullins Riley & Scarborough LLP

Jane E. Remillard, Esq.

Jeanne M. DiGiorgio

Primary Examiner:

Prema M Mertz

Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/40 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); G01N 33/573 (2006.01); A61K 47/68 (2017.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6871 (2017.08); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/303 (2013.01); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 16/3038 (2013.01); C07K 16/3046 (2013.01); C07K 16/3053 (2013.01); C07K 16/3061 (2013.01); C07K 16/3069 (2013.01); G01N 33/573 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/71 (2013.01); C07K 2317/72 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2333/916 (2013.01);
Abstract

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Find Patent Forward Citations

Loading…